Evidence map›Paper›PMID 42717135›Full record

ArticleThe AAPS journal2026

In Vitro Release Testing for Long Acting Injectables - a Workshop Summary Report.

Talia Flanagan, Diane Burgess, Marieta Duvnjak, Nikoletta Fotaki, Kate Harris, Krutika Meena Harish Jain, Dawen Kou, Adam McCartan, Heather Mead, Johanna Milsmann and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Talia FlanaganUCB Pharma SA, CMC Development Sciences, Braine L'Alleud, Belgium.
Diane BurgessUniversity of Connecticut, Department of Pharmaceutical Sciences, Storrs, Connecticut, USA.ORCID http://orcid.org/0000-0002-6471-2109
Marieta DuvnjakNovartis, Analytical Research & Development, Novartis Pharma AG, Basel, Switzerland.ORCID http://orcid.org/0000-0003-1847-5357
Nikoletta FotakiUniversity of Bath, Department of Life Sciences, Claverton Down, UK.ORCID http://orcid.org/0000-0003-1826-7363
Kate HarrisAstraZeneca, Global Product Development, Pharmaceutical Technology & Development, Operations, Macclesfield, UK.ORCID http://orcid.org/0009-0002-9933-4010
Krutika Meena Harish JainGilead Sciences, Analytical Development and Operations, Foster City, California, USA.ORCID http://orcid.org/0000-0002-6195-4372
Dawen KouGenentech, Synthetic Molecule Pharmaceutical Sciences, South San Francisco, California, USA.ORCID http://orcid.org/0000-0001-5713-7161
Adam McCartanUniversity of Bath, Department of Life Sciences, Claverton Down, UK.ORCID http://orcid.org/0000-0002-9289-0463
Heather MeadAstraZeneca, Global Product Development, Pharmaceutical Technology & Development, Operations, Macclesfield, UK.ORCID http://orcid.org/0000-0003-2752-7059
Johanna MilsmannBoehringer Ingelheim Pharma GmbH & Co. KG, Drug Product Development NCE, Biberach, Germany.ORCID http://orcid.org/0000-0002-6001-6341
Randy MrsnyUniversity of Bath, Department of Life Sciences, Claverton Down, UK.ORCID http://orcid.org/0000-0001-8505-8516
Vasiliki ParaskevopoulouAstraZeneca, Global Product Development, Pharmaceutical Technology & Development, Operations, Macclesfield, UK.ORCID http://orcid.org/0000-0001-7065-7209
Sharadvi ThatiBristol Myers Squibb, New Brunswick, New Jersey, USA.ORCID http://orcid.org/0000-0002-6717-8714
Marta VenczelSanofi, Global CMC Development, Sanofi-Aventis Deutschland GmbH, Frankfurt/Main, Germany.ORCID http://orcid.org/0000-0002-1288-999X
David CurranGSK, Analytical Development, 1250 South Collegeville Road, Collegeville, Pennsylvania, 19406, USA. David.w.curran@gsk.com.ORCID http://orcid.org/0000-0003-2095-1172

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A three-session webinar series was held by the IQ Consortium in early May 2023 on the topic of in vitro release testing of long acting injectable and parenteral (non-oral) drug products. Attendance was excellent, indicating the high level of interest in this topic. This paper provides a high-level overview of the talks that were given during the webinar and the open discussion session.

Indexed as

Delayed-Action PreparationsDrug LiberationChemistry, PharmaceuticalHumansInjectionsDelayed-Action Preparationsdissolutionin vitro releaseIQ Consortiumlong acting injectableparenteralwebinarworkshop

Identifiers

PMID42717135

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.